Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
The humoral immunity after SARS-CoV-2 infection or vaccination was examined. Convalescent sera after infection with variants of concern (VOCs: B.1.1.7, <i>n</i> = 10; B.1.351, <i>n</i> = 1) and sera from 100 vaccinees (Pfizer/BioNTech, BNT162b2, <i>n</i> = 33; Mod...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/7/700 |
| _version_ | 1797528754613911552 |
|---|---|
| author | Franziska Neumann Ruben Rose Janine Römpke Olaf Grobe Thomas Lorentz Helmut Fickenscher Andi Krumbholz |
| author_facet | Franziska Neumann Ruben Rose Janine Römpke Olaf Grobe Thomas Lorentz Helmut Fickenscher Andi Krumbholz |
| author_sort | Franziska Neumann |
| collection | DOAJ |
| description | The humoral immunity after SARS-CoV-2 infection or vaccination was examined. Convalescent sera after infection with variants of concern (VOCs: B.1.1.7, <i>n</i> = 10; B.1.351, <i>n</i> = 1) and sera from 100 vaccinees (Pfizer/BioNTech, BNT162b2, <i>n</i> = 33; Moderna, mRNA-1273, <i>n</i> = 11; AstraZeneca, ChAdOx1 nCoV-19/AZD1222, <i>n</i> = 56) were tested for the presence of immunoglobulin G (IgG) directed against the viral spike (S)-protein, its receptor-binding domain (RBD), the nucleoprotein (N) and for virus-neutralizing antibodies (VNA). For the latter, surrogate assays (sVNT) and a Vero-cell based neutralization test (cVNT) were used. Maturity of IgG was determined by measuring the avidity in an immunoblot (IB). Past VOC infection resulted in a broad reactivity of anti-S IgG (100%), anti-RBD IgG (100%), and anti-N IgG (91%), while latter were absent in 99% of vaccinees. Starting approximately two weeks after the first vaccine dose, anti-S IgG (75–100%) and particularly anti-RBD IgG (98–100%) were detectable. After the second dose, their titers increased and were higher than in the convalescents. The sVNT showed evidence of VNA in 91% of convalescents and in 80–100%/100% after first/second vaccine dose, respectively. After the second dose, an increase in VNA titer and IgGs of high avidity were demonstrated by cVNT and IB, respectively. Re-vaccination contributes to a more robust immune response. |
| first_indexed | 2024-03-10T10:03:02Z |
| format | Article |
| id | doaj.art-d4cd0e0db2d741cf9744c3bc083fa2bf |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T10:03:02Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-d4cd0e0db2d741cf9744c3bc083fa2bf2023-11-22T01:47:46ZengMDPI AGVaccines2076-393X2021-06-019770010.3390/vaccines9070700Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or VaccinationFranziska Neumann0Ruben Rose1Janine Römpke2Olaf Grobe3Thomas Lorentz4Helmut Fickenscher5Andi Krumbholz6Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, GermanyInstitut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig-Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, GermanyStädtisches Krankenhaus Kiel, Chemnitzstraße 33, D-24116 Kiel, GermanyLabor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, GermanyLabor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, GermanyInstitut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig-Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, GermanyLabor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, GermanyThe humoral immunity after SARS-CoV-2 infection or vaccination was examined. Convalescent sera after infection with variants of concern (VOCs: B.1.1.7, <i>n</i> = 10; B.1.351, <i>n</i> = 1) and sera from 100 vaccinees (Pfizer/BioNTech, BNT162b2, <i>n</i> = 33; Moderna, mRNA-1273, <i>n</i> = 11; AstraZeneca, ChAdOx1 nCoV-19/AZD1222, <i>n</i> = 56) were tested for the presence of immunoglobulin G (IgG) directed against the viral spike (S)-protein, its receptor-binding domain (RBD), the nucleoprotein (N) and for virus-neutralizing antibodies (VNA). For the latter, surrogate assays (sVNT) and a Vero-cell based neutralization test (cVNT) were used. Maturity of IgG was determined by measuring the avidity in an immunoblot (IB). Past VOC infection resulted in a broad reactivity of anti-S IgG (100%), anti-RBD IgG (100%), and anti-N IgG (91%), while latter were absent in 99% of vaccinees. Starting approximately two weeks after the first vaccine dose, anti-S IgG (75–100%) and particularly anti-RBD IgG (98–100%) were detectable. After the second dose, their titers increased and were higher than in the convalescents. The sVNT showed evidence of VNA in 91% of convalescents and in 80–100%/100% after first/second vaccine dose, respectively. After the second dose, an increase in VNA titer and IgGs of high avidity were demonstrated by cVNT and IB, respectively. Re-vaccination contributes to a more robust immune response.https://www.mdpi.com/2076-393X/9/7/700COVID-19virus variantsvaccinationhumoral immune responseIgGtiter |
| spellingShingle | Franziska Neumann Ruben Rose Janine Römpke Olaf Grobe Thomas Lorentz Helmut Fickenscher Andi Krumbholz Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination Vaccines COVID-19 virus variants vaccination humoral immune response IgG titer |
| title | Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination |
| title_full | Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination |
| title_fullStr | Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination |
| title_full_unstemmed | Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination |
| title_short | Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination |
| title_sort | development of sars cov 2 specific igg and virus neutralizing antibodies after infection with variants of concern or vaccination |
| topic | COVID-19 virus variants vaccination humoral immune response IgG titer |
| url | https://www.mdpi.com/2076-393X/9/7/700 |
| work_keys_str_mv | AT franziskaneumann developmentofsarscov2specificiggandvirusneutralizingantibodiesafterinfectionwithvariantsofconcernorvaccination AT rubenrose developmentofsarscov2specificiggandvirusneutralizingantibodiesafterinfectionwithvariantsofconcernorvaccination AT janinerompke developmentofsarscov2specificiggandvirusneutralizingantibodiesafterinfectionwithvariantsofconcernorvaccination AT olafgrobe developmentofsarscov2specificiggandvirusneutralizingantibodiesafterinfectionwithvariantsofconcernorvaccination AT thomaslorentz developmentofsarscov2specificiggandvirusneutralizingantibodiesafterinfectionwithvariantsofconcernorvaccination AT helmutfickenscher developmentofsarscov2specificiggandvirusneutralizingantibodiesafterinfectionwithvariantsofconcernorvaccination AT andikrumbholz developmentofsarscov2specificiggandvirusneutralizingantibodiesafterinfectionwithvariantsofconcernorvaccination |